NEW YORK, Aug. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Genetic Testing Industry
http://www.reportlinker.com/p02284877/Global-Genetic-Testing-Industry.html
This report analyzes the worldwide markets for Genetic Testing in US$ Million by the following Product Segments: Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 73 companies including many key and niche players such as -
Abbott Laboratories
AutoGenomics, Inc.
BioRad Laboratories
ELITech Group S.P.A
PerkinElmer, Inc.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Prenatal Diagnosis and Newborn Genetic Testing I-3
Pharmacogenetics/Pharmacogenomics I-4
Predictive Testing I-4
II. EXECUTIVE SUMMARY
1. GLOBAL MARKET OVERVIEW II-1
A Curtain Raiser II-1
Top Ten Genetic Disorders Worldwide II-1
Genetic Testing: Heralding a New Era II-2
Genetic Testing Paves the Way for Personalized Medicine II-4
Table 1: Drug Ineffectiveness for Select Therapeutic
Categories - Necessitating Personalized Medicine (includes
corresponding Graph/Chart) II-5
Ballooning Global Population Offers Increased Growth
Opportunities II-5
Table 2: Top 25 Countries Worldwide in Terms of Population:
2007, 2010 & 2013 (includes corresponding Graph/Chart) II-6
Aging Population Drives the Genetic Testing Market II-7
Table 3: Global Population Statistics for the 65+ Age Group
(2012) (includes corresponding Graph/Chart) II-8
Table 4: Elderly Population (65+ Years) as a % of Total
Population (2025) (includes corresponding Graph/Chart) II-9
Improving Healthcare Expenditure to Drive Demand II-9
Table 5: Per-Capita Healthcare Expenditure in Select Regions:
2013 (includes corresponding Graph/Chart) II-10
Table 6: Healthcare Spending as a Percentage of GDP: 2012
(includes corresponding Graph/Chart) II-11
Genetic Testing - A Critical Part of the Rapidly Developing
In-Vitro Diagnostics (IVD) Market II-11
Table 7: Global In Vitro Diagnostics (IVD) Market by
Geographic Region (2013): Percentage Share Breakdown of
Revenues for the United States, Europe, and Rest of World
(includes corresponding Graph/Chart) II-12
Table 8: Global In-Vitro Diagnostics Market by Sector (2013):
Percentage Breakdown of Revenues for Hospital & Commercial
Laboratories, and Decentralized & Patient Self-Testing
(includes corresponding Graph/Chart) II-12
Table 9: Global In-Vitro Diagnostics Market by Segment
(2013): Percentage Breakdown of Value Sales for Hematology,
Hemostasis, Immunochemistry, Microbiology, Molecular
Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood
Glucose, and Tissue Diagnostics (includes corresponding
Graph/Chart) II-13
Table 10: Global In Vitro Diagnostics Market by Leading
Player (2013): Percentage Share Breakdown of Revenues for
Abbott, Biomerieux, Danaher, J&J, Roche, Siemens and Others
(includes corresponding Graph/Chart) II-13
Genetic Testing: The Rapidly Growing Segment of Molecular
Diagnostics Market II-13
Table 11: Global Molecular Diagnostics Market (2013):
Percentage Breakdown of Market Revenues of Infectious Disease
Testing, Genomics, and Blood Donor Screening (includes
corresponding Graph/Chart) II-14
Biomarker Discovery Leads to Advanced Genetic Testing II-14
List of US-FDA Approved Biomarkers for Cancer II-15
2. SEGMENTAL REVIEW II-17
Prenatal Testing Market to Rise II-17
List of Genetic Disorders by Event, Genetic Manifestation and
Prevalence II-17
Prenatal Testing - Changing the World of Pregnancy Care II-18
Prenatal Testing - A Rudimentary Overview II-18
List of Available Prenatal Screening and Diagnostic Tests by
Indication II-18
Conventional Pre-Natal Diagnostic Techniques - A Risky Affair II-19
Other Negativities of Existing Invasive Techniques II-19
Emergence of Non-Invasive Prenatal Diagnosis (NIPD) II-19
Competition Intensifies in the NIPD Market II-20
Commercially Available NIPD (Genetic) Tests for Aneuploidy
in the US II-21
NIPD Eliminates Risks and Uncertainty of Conventional
Diagnostic Procedures II-21
Opposition to NIPD Technique - A Significant Hurdle to Adoption II-21
Ethical Issues Bog Down Benefits and Proliferation of
Prenatal Testing II-22
Benefits Outweigh Snags in NIPD Tests II-22
Major Factors Influencing Penetration of NIPD Tests II-22
Table 12: Price Comparison of Existing Tests and Screening
Procedures for Down's syndrome II-23
Diversity in NIPD Usage on the Cards II-23
Expanded Newborn Screening II-23
Predictive Diagnostics II-24
Breast Cancer Gene Testing Market to Expand Strongly II-24
Myriad Genetics - The Unquestioned Leader in Breast Cancer
Testing II-25
Routine Clinical Testing Vs. Predictive Genetic Testing II-25
Increasing Incidence and Prevalence of CDDs: A Major Growth
Driver II-26
Discovery of Novel Biomarkers Crucial to Predictive Diagnostics II-26
Unresolved Issues Hamper Widespread Implementation of Genetic
Diagnosis and Testing for Monogenetic Disease II-27
Dearth of Genetic Counselors - A Major Hurdle for the
Predictive Genetic Testing II-28
Pharmacogenomics Development Augurs Growth of Genetic Testing
Market II-28
3. MARKET TRENDS II-29
Direct-to-Consumer Genetic Testing - A Key Trend in the
Genetic Testing Market II-29
Creating a Platform for New Companies II-29
Business Models for DTC Genetic Testing Firms II-30
Growing Prominence of DTC Genetic Testing: A Boon or a Curse? II-30
Pre-implantation Genetic Diagnosis (PGD) - A Major Driver for
the Genetic Testing Market II-30
Whole Genome Sequencing - Boon or Bane to Genetic Testing? II-31
Validity of Emerging Genetic Tests for Alzheimer's II-32
Utility of Genetic Testing for Warfarin Study II-32
Oncology - A Key Focus Area for Genetic Testing II-32
Table 13: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America & The Caribbean, and Africa (includes corresponding
Graph/Chart) II-33
Table 14: New Cancer Cases in the World by Affected Site
(2012) (in Thousands) (includes corresponding Graph/Chart) II-34
Table 15: Cancer Incidence in Developed Nations by Site: 2012
(includes corresponding Graph/Chart) II-35
Table 16: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung &
Bronchus, Prostate, Colorectal, and Liver Cancers (includes
corresponding Graph/Chart) II-36
Table 17: Global Incidence of Common Cancers in Women (2012):
Number of New Cases Reported in Thousands for Breast,
Colorectal, Lung & Bronchus, and Liver Cancers (includes
corresponding Graph/Chart) II-36
Table 18: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths (in Thousands)
for Asia-Oceania, Europe, North America, Latin America & The
Caribbean, and Africa (includes corresponding Graph/Chart) II-37
Genetic Testing May Aid CNS Disease Therapeutics II-37
Neurodegenerative Diseases - Major Focus Area for Genetic Testing II-38
Alzheimer's Disease II-38
Huntington's Disease II-39
Genetic Testing - An Indispensible Tool for Cystic Fibrosis II-41
Table 19: Most Common Mutations and Worldwide Frequency
(includes corresponding Graph/Chart) II-41
Histocompatibility Testing II-42
Table 20: Global HLA Testing Market (2012-2016E): Revenue
Estimates for 2012, 2013, 2014, 2015, and 2016 (includes
corresponding Graph/Chart) II-42
Next-Generation Sequencing - A Giant Leap in Genome Sequencing II-42
Pediatric Genetic Testing for Screening Adult Onset Disorders
Fast Gaining Acceptance II-43
Better Regulatory Safeguards Required for Global Genetic
Testing Industry II-43
Challenges Faced II-44
Genetic Counseling: Gaining Momentum II-45
Online Approach Gains Momentum II-45
Recommendations of ACOG and ACGM Augments Demand for Cystic
Fibrosis Testing II-45
Ethical Issues & Need for Appropriate Regulating Policies II-46
Issues Related to Genetic Tests for Obesity II-47
Diagnosis and Treatment during Pregnancy - An Effective Way of
Alleviating Syphilis Related Deaths and Stillbirths II-47
4. MOLECULAR DIAGNOSTICS MARKET - AN INSIGHT II-48
Global Molecular Diagnostics on a High Growth Curve II-48
Automation Driving Global Market II-48
Molecular Diagnostics: Marking the Convergence of Numerous
Technologies II-48
MDx Market for Infectious Diseases Zooming Ahead II-48
Aging Population, Disease Incidence - Fundamental Drivers of
Growth II-48
Pharmaceutical Firms Carving Their Niche in Molecular
Diagnostics Market II-49
Towards Tailoring the Right Treatment for the Right Disease II-49
Limited Reimbursements by Third Party Payers - A Stumbling Block II-49
Disease-Specific Molecular Diagnostics to Deliver Improved
Clinical Outcomes II-50
Molecular Diagnostics and Intellectual Property II-50
Business Opportunities in the Offing II-50
Medical Training and Practice Challenges II-51
Hurdles All the Way for Companies Eyeing Molecular Diagnostics II-51
Product Marketing - Key to Commercial Success II-52
Integration of Molecular Diagnostics into Therapeutics II-52
Molecular Diagnostics - Moving from Centralization to
Decentralization II-52
Migrating to Decentralized Format II-53
Going Ahead with Decentralization II-53
Competitive Landscape of the Molecular Diagnostics Market II-54
Table 21: Global Molecular Diagnostics Market by Leading
Players (2012): Market Share Breakdown for Abbott, BD,
Cepheid, Hologic Gen-Probe, Novartis Dx, Qiagen, Roche,
Siemens Dx, and Others (includes corresponding Graph/Chart) II-54
New Entrants Eye Unmet Needs II-54
5. PRODUCT OVERVIEW II-55
Preface to Genetic Testing II-55
Genetic Testing and its Applications II-55
Gene Candidate and Genome Screen II-56
'DNA Chip' to Chip into Genetic Field II-56
Techniques Used to Identify Changes in Genes II-57
Types of Genetic Testing II-57
Prenatal Diagnosis II-57
Cancer Testing II-57
Carrier Identification II-58
Newborn Screening II-58
Predictive Testing II-58
Pre-Symptomatic Testing II-58
Cytogenetic Tests II-58
Steps in Genetic Testing Process II-59
Limitations II-59
Risks and Other Limitations of Genetic Testing II-59
Medical Institutions to Reap the Benefit of Genetic Testing II-59
Pharmacogenetics/Pharmacogenomics II-60
Review of Select Genetic Tests II-60
Cystic Fibrosis II-60
Breast and Ovarian Cancer (BRCA) II-60
Alzheimer's Disease II-60
Colorectal Cancer II-60
Haemochromatosis (HH) II-60
Cowden Syndrome II-61
Huntington's Disease (HD) II-61
Costs of Select Tests II-61
Table 22: Costs of Select Genetic Tests II-61
GENETIC TESTING TECHNIQUES II-61
Signal Amplification Technologies II-61
PCR - New Developments II-61
Quantitative Real-Time PCR for Molecular Diagnostics II-62
Signal Detection and Quantification II-62
Quantitative Real-Time RT-PCR Analysis II-62
Applications of Quantitative Real-Time PCR Analysis II-63
Viral Detection and Viral-Load Monitoring II-63
Sensitive Detection of Infectious Disease Agents II-63
Predisposition Testing II-63
Non-PCR Methods II-63
Other Signal Amplification Technologies II-63
DNA Probe Based Products II-63
Direct Detection of Specific Nucleic Acid Sequences II-64
Nucleic Acid Amplification and Detection II-64
DNA Sequencing and Gene Detection II-64
Arrays of Immobilized Probes (DNA Chips) in Gene Detection II-65
RNA Diagnostics II-65
6. PRODUCT LAUNCHES/INNOVATIONS II-66
Courtagen Launches Genetic Sequencing Tests for
Neurodevelopmental Disorders II-66
Myriad Genetics Launches EndoPredict® Breast Cancer Test II-66
Assurex Health Expands GeneSight® Pharmacogenomic Testing
Platform II-66
Illumina to Launch VeriSeq Embryo Screening Tool II-66
GENEWIZ Launches PGxOne™ Pharmacogenomic Test II-66
Ambry Genetics Launches ExomeNext™ and ExomeNext-Rapid™
Genetic Tests II-66
Pathway Genomics Launches Genetic Test to Detect Risk of
Colorectal Cancer II-67
Mount Sinai Laboratory Develops Accurate Genetic Test for SMA II-67
Sequenom Launches Non-Invasive Prenatal Test by Laboratoire Cerba II-67
CSL Behring Launches Antitrypsin Deficiency Screening Test II-67
Interleukin Genetics Launches PerioPredict™ II-67
US Genomic Health Reports Positive Data from Oncotype DX
Prostate Cancer Study II-67
Assurex Health Launches GeneSight Test to Predict Folic Acid
Conversion and Treat Depression II-67
Verifi ® Prenatal Test Available Through California Prenatal
Screening Program II-68
Children's Mercy Launches TaGSCAN Test II-68
General Genetics and Estrogen Gene Test Launch EstroGene™ Test II-68
Genetic Analysis Launches GA-map™ Test II-68
Myriad Genetics Launches myRisk™ Hereditary Cancer Test II-68
GeneDx Launches Genetic Tests for Cancer II-68
ArcticDx Launches Vita Risk Pharmacogenetic Test for AMD Patients II-69
Quest Diagnostics Launches CYP450 Biomarker-based Diagnostic Test II-69
Blueprint Genetics Launches Gene Sequencing Tests II-69
Bioiberica Farma Launches Genetic Test for Osteoarthritis II-69
Illumina, The Wellcome Trust Centre and the Institute of
Cancer Research Roll out Genetic Test II-69
Aviir to Launch Genetic Testing for Inherited Cardiovascular
Disease II-69
Oxford University Hospitals Launches 46-gene Sequencing Test
for Cancer II-70
Millennium Labs Launches Millennium PGT Testing II-70
NutraGene Unveils Genetic Testing for Type2 Diabetes II-70
IntegraGen Unveils ARISk™ Test for Autism II-70
7. RECENT INDUSTRY ACTIVITY II-71
Cancer Genetics Acquires BioServe Biotechnologies II-71
PerkinElmer to Close Its Signature Genomics Testing Business II-71
LifeLabs Medical Laboratory Services Buys out Centogene's
Canadian Business II-71
CytoScan Dx Assay by Affymetrix Receives FDA Approval II-71
Sequenom and CombiMatrix Enter Marketing Agreement for
Chromosomal Microarray Analysis II-71
Illumina Acquires Verinata Health II-72
Gene Security Network Changes Name to Natera II-72
TrovaGene Acquires MultiGEN Diagnostics II-72
Adaptive TCR Corp. is now Adaptive Biotechnologies II-72
TrovaGene Acquires Exclusive License on SF3B1 Mutations II-72
8. FOCUS ON SELECT GLOBAL PLAYERS II-73
Abbott Laboratories (US) II-73
Abbott Molecular, Inc. (US) II-73
AutoGenomics, Inc. (US) II-74
BioRad Laboratories (US) II-74
ELITech Group S.P.A. (France) II-75
PerkinElmer, Inc. (US) II-76
Quest Diagnostics, Inc. (US) II-76
Roche Diagnostics Corp. (Switzerland) II-77
Roche Molecular Diagnostics, Inc. (US) II-78
Thermo Fisher Scientific (US) II-78
Transgenomic, Inc. (US) II-79
9. GLOBAL MARKET PERSPECTIVE II-80
Table 23: World Recent Past, Current & Future Analysis for
Genetic Testing by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2013 through 2020 (includes corresponding Graph/Chart) II-80
Table 24: World Historic Review for Genetic Testing by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2006 through 2012
(includes corresponding Graph/Chart) II-81
Table 25: World 15-Year Perspective for Genetic Testing by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for Years 2006, 2014 & 2020 (includes corresponding
Graph/Chart) II-82
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
The US: Leading Market for Genetic Testing Globally III-1
Demographic Changes Offer Growth Opportunities III-1
Table 26: North American Aging Population by Age Group:
1975-2050 (includes corresponding Graph/Chart) III-2
Burgeoning Potential for Genetic Testing III-2
Predictive Screening: Another Growth Area III-3
An important Market for Personalized Medicine III-3
Epidemic Proportion of Cancer in the US - Driver for Cancer
Genetic Testing III-3
Table 27: New Cancer Cases by Gender and Affected Site in
the US (2013) (includes corresponding Graph/Chart) III-4
Newborn Testing Gains Ground III-5
Success Stories III-5
Favorable Reimbursement Policies III-6
Favorable Insurance Coverage for Cystic Fibrosis Genetic
Testing III-6
Table 28: CF Carrier Screening: Percentage Breakdown of
Population by Coverage Policy: 2012 (includes corresponding
Graph/Chart) III-6
Table 29: CF Diagnostic Testing: Percentage Breakdown of
Population by Coverage Policy: 2012 (includes corresponding
Graph/Chart) III-7
Popularity of Screening and ACOG Guidelines Sink Invasive
Prenatal Diagnosis Numbers III-7
Table 30: US Annual Pregnancies by Age Group/Risk Profile:
2010 (includes corresponding Graph/Chart) III-7
Tough Market Prospects for Sex Determination Tests III-8
Sequenom Bets Big on MaterniT21 III-8
IP Landscape of NIPD Tests III-8
Table 31: List of Number of Patents Held by
Companies/Institutions Offering NIPT: 2012 (includes
corresponding Graph/Chart) III-9
US Patents of cff DNA-based NIPD Tests III-10
Direct-to-Consumer Testing - A Growing Market III-11
DTC Genetic Tests Provide POCT for Patients in Hospice Care III-11
Regulatory Environment III-11
Genetic Information Nondiscrimination Act Boosts Genetic
Testing III-12
NIH Launches Public Database III-12
Stricter Regulations for DTC Genetic Testing III-12
Product Launches III-13
Strategic Corporate Developments III-17
Select Key Players III-18
B.Market Analytics III-24
Table 32: The US Recent Past, Current & Future Analysis for
Genetic Testing by Segment - Prenatal and Newborn Genetic
Testing, Pharmacogenomic Testing, and Predictive Medicine
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-24
Table 33: The US Historic Review for Genetic Testing by
Segment - Prenatal and Newborn Genetic Testing,
Pharmacogenomic Testing, and Predictive Medicine Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-25
Table 34: The US 15-Year Perspective for Genetic Testing by
Segment - Percentage Breakdown of Dollar Sales for Prenatal
and Newborn Genetic Testing, Pharmacogenomic Testing, and
Predictive Medicine Markets for Years 2006, 2014 & 2020
(includes corresponding Graph/Chart) III-26
2. CANADA III-27
A.Market Analysis III-27
Rising Incidence of Chronic Diseases Spurs Genetic Testing
Demand III-27
Table 35: New Cancer Cases in Canada by Gender and Affected
Site: 2012 (includes corresponding Graph/Chart) III-28
Table 36: New Cancer Cases in Canada by Province: 2012
(includes corresponding Graph/Chart) III-29
Table 37: New Cancer Cases in Canada by Age Group and
Gender: 2012 (includes corresponding Graph/Chart) III-30
Product Launch III-30
Strategic Corporate Development III-31
B.Market Analytics III-31
Table 38: Canadian Recent Past, Current & Future Analysis
for Genetic Testing Market Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-31
Table 39: Canadian Historic Review for Genetic Testing
Market Analyzed with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-32
3. JAPAN III-33
A.Market Analysis III-33
Demographics Drive Market Growth III-33
Table 40: Percentage Breakdown of Japanese Population by
Age Group (2012) (includes corresponding Graph/Chart) III-33
Table 41: Japanese 65+ Years Population: 1950-2010
(includes corresponding Graph/Chart) III-34
DTC Genetic Testing Regulatory Scenario III-34
B.Market Analytics III-35
Table 42: Japanese Recent Past, Current & Future Analysis
for Genetic Testing Market Analyzed with Annual Revenue
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-35
Table 43: Japanese Historic Review for Genetic Testing
Market Analyzed with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-36
4. EUROPE III-37
A.Market Analysis III-37
Debt Crisis in Europe Affects Healthcare Industry III-37
European Healthcare System: In a State of Transition? III-37
An Insight into Molecular Diagnostics Markets in Europe III-38
Cancer Trends III-38
Table 44: Cancer Incidence in Europe by Site: 2012 (in
Thousands) (includes corresponding Graph/Chart) III-39
Aging Population to Drive Demand for Genetic Testing III-39
Table 45: Population Breakup by Age Group for Select
European Countries: 2012 (As a % of Total Population)
(includes corresponding Graph/Chart) III-40
European Personalized Medicine Market to Exhibit Robust Growth III-40
Legislations/Regulatory Policies in Select European Countries III-41
Legislations Governing Genetic Testing in Select European
Countries III-42
B.Market Analytics III-43
Table 46: European Recent Past, Current & Future Analysis
for Genetic Testing by Geographic Region - France, Germany,
Italy, UK, and Rest of Europe Markets Independently Analyzed
with Annual Revenue Figures in US$ Million for Years 2013
through 2020 (includes corresponding Graph/Chart) III-43
Table 47: European Historic Review for Genetic Testing by
Geographic Region - France, Germany, Italy, UK, and Rest of
Europe Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-44
Table 48: European 15-Year Perspective for Genetic Testing
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, and Rest of Europe Markets
for Years 2006, 2014 & 2020 (includes corresponding
Graph/Chart) III-45
4a. FRANCE III-46
A.Market Analysis III-46
Regulatory Environment in France III-46
Product Launch III-46
ELITech Group s.p.a. - A Key Player III-46
B.Market Analytics III-47
Table 49: French Recent Past, Current & Future Analysis for
Genetic Testing Market Analyzed with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-47
Table 50: French Historic Review for Genetic Testing Market
Analyzed with Annual Revenue Figures in US$ Million for
Years 2006 through 2012 (includes corresponding Graph/Chart) III-48
4b. GERMANY III-49
A.Market Analysis III-49
Parliamentary Regulations III-49
B.Market Analytics III-50
Table 51: German Recent Past, Current & Future Analysis for
Genetic Testing Market Analyzed with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-50
Table 52: German Historic Review for Genetic Testing Market
Analyzed with Annual Revenue Figures in US$ Million for
Years 2006 through 2012 (includes corresponding Graph/Chart) III-51
4c. ITALY III-52
Market Analysis III-52
Table 53: Italian Recent Past, Current & Future Analysis for
Genetic Testing Market Analyzed with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-52
Table 54: Italian Historic Review for Genetic Testing Market
Analyzed with Annual Revenue Figures in US$ Million for
Years 2006 through 2012 (includes corresponding Graph/Chart) III-53
4d. THE UNITED KINGDOM III-54
A.Market Analysis III-54
Increased Support for Personalized Medicine to Drive Genetic
Testing III-54
SMIP for Pharmacogenomic Testing III-54
Increasing Need for Less Risky Prenatal Diagnostic Methods
in the UK III-54
Regulatory Scenario III-55
Non-consensual Analysis of DNA Made Illegal III-55
Principles for DTC Genetic Testing Laid out by HGC III-55
Product launches III-55
B.Market Analytics III-56
Table 55: The UK Recent Past, Current & Future Analysis for
Genetic Testing Market Analyzed with Annual Revenue Figures
in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-56
Table 56: The UK Historic Review for Genetic Testing Market
Analyzed with Annual Revenue Figures in US$ Million for
Years 2006 through 2012 (includes corresponding Graph/Chart) III-57
4e. REST OF EUROPE III-58
A.Market Analysis III-58
Product Launches III-58
Roche Diagnostics Corp. - A Key Player (Switzerland) III-58
B.Market Analytics III-60
Table 57: Rest of European Recent Past, Current & Future
Analysis for Genetic Testing Market Analyzed with Annual
Revenue Figures in US$ Million for Years 2013 through 2020
(includes corresponding Graph/Chart) III-60
Table 58: Rest of European Historic Review for Genetic
Testing Market Analyzed with Annual Revenue Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-61
5. ASIA-PACIFIC III-62
A.Market Analysis III-62
Healthcare Spending in Asia-Pacific: On the Rise III-62
Select Regional Markets III-62
China III-62
China's FDA Curbs Prenatal Testing III-62
Table 59: China - The Most Populous Country Worldwide
(July 2013): Total Population (in Millions) by Age Group
0-14 Years, 15-44 Years, 45-64 Years, and 65+ Years for
China Vis-a-Vis Other Countries (includes corresponding
Graph/Chart) III-63
Table 60: China - The Most Populous Country Worldwide
(July 2013): Percentage Population by Age Group 0-14
Years, 15-44 Years, 45-64 Years, and 65+ Years for China
Vis-a-Vis Other Countries (includes corresponding
Graph/Chart) III-64
Diagnostics Market in India III-64
Australia and New Zealand III-65
Approval of Experiments on Human Embryos in New Zealand III-65
Singapore Sets Guidelines for Genetic Research and Testing III-65
Product Launch III-66
Strategic Corporate Developments III-66
B.Market Analytics III-67
Table 61: Asia-Pacific Recent Past, Current & Future
Analysis for Genetic Testing Market Analyzed with Annual
Revenue Figures in US$ Million for Years 2013 through 2020
(includes corresponding Graph/Chart) III-67
Table 62: Asia-Pacific Historic Review for Genetic Testing
Market Analyzed with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-68
6. REST OF WORLD III-69
Market Analysis III-69
Table 63: Rest of World Recent Past, Current & Future
Analysis for Genetic Testing Market Analyzed with Annual
Revenue Figures in US$ Million for Years 2013 through 2020
(includes corresponding Graph/Chart) III-69
Table 64: Rest of World Historic Review for Genetic Testing
Market Analyzed with Annual Revenue Figures in US$ Million
for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-70
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 73 (including Divisions/Subsidiaries - 79)
The United States (56)
Canada (3)
Europe (18)
- France (2)
- Germany (3)
- The United Kingdom (3)
- Spain (1)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (2)
To order this report: Global Genetic Testing Industry
http://www.reportlinker.com/p02284877/Global-Genetic-Testing-Industry.html
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article